Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Madmanmadoxon Jun 01, 2020 9:05am
205 Views
Post# 31095443

Efficacy Reached!

Efficacy Reached! Efficacy Reached! :) . Previously proven to clinically be safer on the gut; now clinically proven to be effective for pain relieve! Taken together, one can extrapolate Naproxen is now clinically proven to be inferior drug in its Rx for pain relieve!

Congrats to Antibe Therapeutics, especially John Wallace. It is not everyday we can significantly improve on a go to perscription! Improving the world we live in is no small feat. :). I know more than a few people who have ulcer's from their stomach all the way up into their esophagus who have had to make the decision to stop Naproxen and take full on the pain instead. I cant wait to tell them the hope coming down the pipeline to keep em going. Good job taking GI Science by the horns and solving a problem that has been the primary issue with Cox inhibition for decades...
Bullboard Posts